Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer

Autophagy

Volumn 11, Issue 10, 2015, Pages 1878-1890

  Ladoire, Sylvain ^a,b   Penault Llorca, Frédérique ^c,d   Senovilla, Laura ^e,f   Dalban, Cécile ^g   Enot, David ^f   Locher, Clara ^b   Prada, Nicole ^b   Poirier Colame, Vichnou ^b   Chaba, Kariman ^e,h   Arnould, Laurent ^a   Ghiringhelli, François ^a,i   Fumoleau, Pierre ^a   Spielmann, Marc ^f   Delaloge, Suzette ^f   Poillot, Marie Laure ^g   Arveux, Patrick ^g   Goubar, Aicha ^f   Andre, Fabrice ^f   Zitvoge, Laurence ^b,j,k   Kroemer, Guido ^b,f,l  

^a Georges François Leclerc Center   (France)

^b INSERM   (France)

^c CENTRE JEAN PERRIN   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g CENTRE GEORGES FRANÇOIS LECLERC   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ UNIVERSITÉ DE BOURGOGNE   (France)

^j UNIVERSITÉ PARIS SACLAY   (France)

^k Center of Clinical Investigations in Biotherapies of Cancer   (France)

^l HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

Breast cancer; Histology; HMGB1; LC3; Pathology; Prognostic; Tumor microarray

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; HIGH MOBILITY GROUP B1 PROTEIN; LC3B PROTEIN; PROTEIN; UNCLASSIFIED DRUG; MAP1LC3B PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SPECIFIC SURVIVAL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ADJUVANT CHEMOTHERAPY; AUTOPHAGY; BREAST NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; RECURRENT DISEASE; RISK FACTOR;

AUTOPHAGY; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; RECURRENCE; RISK FACTORS;

EID: 84949639567     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.1080/15548627.2015.1082022     Document Type: Article

References (43)

1. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart- Gebhart M, Thurlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24:2206-23; PMID:23917950
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52; PMID:10963602; http://dx.doi.org/10.1038/35021093
3. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, JohnsenH, HastieT, EisenMB, van deRijnM, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869-74; PMID:11553815; http://dx.doi.org/10.1073/pnas.191367098
4. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009; PMID:12490681; http://dx.doi.org/10.1056/NEJMoa021967
5. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360:790-800; PMID:19228622; http://dx.doi.org/10.1056/NEJMra0801289
6. Andre F, Nowak F, Arnedos M, Lacroix L, Viens P, Calvo F. Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. Clin Cancer Res 2012; 18:1555-60; PMID:22422408; http://dx.doi.org/10.1158/1078-0432.CCR-11-2201
7. Aita VM, Liang XH, Murty VV, Pincus DL, Yu W, Cayanis E, Kalachikov S, Gilliam TC, Levine B. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999; 59:59-65; PMID:10395800; http://dx.doi.org/10.1006/geno.1999.5851
8. Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A 2003; 100:15077-82; PMID:14657337; http://dx.doi.org/10.1073/pnas.2436255100
9. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest 2003; 112:1809-20; PMID:14638851; http://dx.doi.org/10.1172/JCI20039
10. Cicchini M, Chakrabarti R, Kongara S, Price S, Nahar R, Lozy F, Zhong H, Vazquez A, Kang Y, Karantza V. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity. Autophagy 2014; 10:2036-52;PMID:25483966
11. Tang H, Sebti S, Titone R, Zhou Y, Isidoro C, Ross TS, Hibshoosh H, Xiao G, Packer M, Xie Y, et al. Decreased mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis. EBioMedicine 2015; 2:255-63; PMID:25825707; http://dx.doi.org/10.1016/j.ebiom.2015.01.008
12. Rosenfeldt MT, O’Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013; 504:296-300; PMID:24305049; http://dx.doi.org/10.1038/nature12865
13. Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, Sykacek P, Frank L, Schramek D, Komnenovic V, et al. A dual role for autophagy in a murine model of lung cancer. Nat Commun 2014; 5:3056; PMID:24445999; http://dx.doi.org/10.1038/ncomms4056
14. Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ III, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010; 190:881-92; PMID:20819940; http://dx.doi.org/10.1083/jcb.200911078
15. Tang D, Kang R, Livesey KM, Kroemer G, Billiar TR, Van Houten B, Zeh HJ III, Lotze MT. High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 2011; 13:701-11; PMID:21641551; http://dx.doi.org/10.1016/j.cmet.2011.04.008
16. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622
17. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347
18. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S, Kepp O, Métivier D, Galluzzi L, Perfettini JL, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014; 21:79-91; PMID:23852373; http://dx.doi.org/10.1038/cdd.2013.75
19. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028
20. Ladoire S, Chaba K, Martins I, Sukkurwala AQ, Adjemian S, Michaud M, Poirier-Colame V, Andreiuolo F, Galluzzi L, White E, et al. Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy 2012; 8:1175-84; PMID:22647537; http://dx.doi.org/10.4161/auto.20353
21. Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2014; 21:69-78; PMID:23811849; http://dx.doi.org/10.1038/cdd.2013.72
22. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008; 4:151-75; PMID:18188003; http://dx.doi.org/10.4161/auto.5338
23. Tanida I,Waguri S. Measurement of autophagy in cells and tissues. Methods Mol Biol 2010; 648:193-214; PMID:20700714; http://dx.doi.org/10.1007/978-1-60761-756-3_13
24. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/10.4161/auto.19496
25. Ladoire S, Hannani D, Vetizou M, Locher C, Aymeric L, Apetoh L, Kepp O, Kroemer G, Ghiringhelli F, Zitvogel L, et al. Cell-death-associated molecular patterns as determinants of cancer immunogenicity. Antioxid Redox Signal 2013; 20:1098-116; PMID:23394620; http://dx.doi.org/10.1089/ars.2012.5133
26. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 1997; 47:28-51;
27. PMID:8996077
28. Chen S, Jiang YZ, Huang L, Zhou RJ, Yu KD, Liu Y, Shao ZM. The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Clin Cancer Res 2013; 19:6853-62; PMID:24141623; http://dx.doi.org/10.1158/1078-0432.CCR-13-1617
29. Suman S, Das TP, Reddy R, Nyakeriga AM, Luevano JE, Konwar D, Pahari P, Damodaran C. The pro-apoptotic role of autophagy in breast cancer. Br J Cancer 2014; 111:309-17; PMID:24945999; http://dx.doi.org/10.1038/bjc.2014.203
30. Kim JY, Jung WH, Koo JS. Expression of Autophagy- Related Proteins According to Androgen Receptor and HER-2 Status in Estrogen Receptor-Negative Breast Cancer. PLoS One 2014; 9:e105666;
31. PMID:25140630
32. Lazova R, Camp RL, Klump V, Siddiqui SF, Amaravadi RK, Pawelek JM. Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res 2012; 18:370-9; PMID:22080440; http://dx.doi.org/10.1158/1078-0432.CCR-11-1282
33. Zhao H, Yang M, Zhao J, Wang J, Zhang Y, Zhang Q. High expression of LC3B is associated with progression and poor outcome in triple-negative breast cancer. Med Oncol 2013; 30:475; PMID:23371253; http://dx.doi.org/10.1007/s12032-013-0475-1
34. He Y, Zhao X, Subahan NR, Fan L, Gao J, Chen H. The prognostic value of autophagy-related markers beclin-1 and microtubule-associated protein light chain 3B in cancers: a systematic review and meta-analysis. Tumour Biol 2014; 35:7317-26; PMID:24838948; http://dx.doi.org/10.1007/s13277-014-2060-4
35. Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, et al. Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. Eur J Clin Invest 2013; 43:286-91; PMID:23410002; http://dx.doi.org/10.1111/eci.12043
36. Stoetzer OJ, Fersching DM, Salat C, Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V, Siegele B, et al. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol 2013; 34:81-90; PMID:22983919; http://dx.doi.org/10.1007/s13277-012-0513-1
37. Huebener P, Gwak GY, Pradere JP, Quinzii CM, Friedman R, Lin CS, Trent CM, Mederacke I, Zhao E, Dapito DH, et al. High-mobility group box 1 is dispensable for autophagy, mitochondrial quality control, and organ function in vivo. Cell Metab 2014; 19:539-47; PMID:24606906; http://dx.doi.org/10.1016/j.cmet.2014.01.014
38. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 2012; 11:709-30; PMID:22935804; http://dx.doi.org/10.1038/nrd3802
39. Madeo F, Pietrocola F, Eisenberg T, Kroemer G. Caloric restriction mimetics: towards a molecular definition. Nat Rev Drug Discov 2014; PMID:25212602
40. Lee HS, Daniels BH, Salas E, Bollen AW, Debnath J, Margeta M. Clinical utility of LC3 and p62 immunohistochemistry in diagnosis of drug-induced autophagic vacuolar myopathies: a case-control study. PLoS One 2012; 7:e36221; PMID:22558391
41. Choi J, Jung W, Koo JS. Expression of autophagyrelated markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Histopathology 2013; 62:275-86; PMID:23134379; http://dx.doi.org/10.1111/his.12002
42. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Computational Statistics & Data Analysis 2003; 43:121-37; http://dx.doi.org/10.1016/S0167-9473(02)00225-6
43. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97:1180-4; PMID:16106022; http://dx.doi.org/10.1093/jnci/dji237